First artificial heart patient dies:
This article was originally published in Clinica
The first recipient of Abiomed's totally implantable artificial heart, AbioCor, has died nearly five months after receiving the device. The patient's death followed severe abdominal bleeding and was not caused by malfunction of the device, according to his physician, Dr Robert Dowling, of the Jewish Hospital in Louisville, Kentucky. Prior to his implant, the patient was not expected to live for more than 30 days. Abiomed, of Danvers, Massachusetts, recently gained US FDA go-ahead to continue with its AbioCor clinical trial (see Clinica No 986, p 20).
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.